HOME >> MEDICINE >> NEWS
Brain-imaging study sheds more light on underlying cause of attention-deficit hyperactivity syndrome

Results of a US study in this week's issue of THE LANCET provide details of the underlying physical causes of attention-deficit hyperactivity syndrome, with reductions in size of some brain areas and an increase in grey matter proportions being characteristic of children with the disorder.

Attention-deficit hyperactivity disorder (ADHD) is a serious neuropsychiatric problem in schoolchildren (an estimated 3-6% of US schoolchildren are affected, for example). The disorder is characterised by poor attention span, impulsivity, and high motor activity. Its nature and cause are poorly understood, although previous research has suggested that structural changes in areas of the brain controlling attention are responsible for the disorder.

Elizabeth R Sowell, Assistant Professor of Neurology from the Laboratory of Neuro Imaging at the University of California Los Angeles, USA, and colleagues undertook the first detailed morphological study using high-resolution magnetic resonance imaging (MRI) and sophisticated computational systems to more accurately determine the specific areas of the brain underlying ADHD. Brain assessment of 27 children (11 girls, 16 boys) and adolescents with ADHD was compared with that of 46 control children without ADHD who were matched for age and sex.

Abnormal brain structure was observed in the frontal cortices (on both sides of the brain) of children with ADHD, with reduced regional brain size localised mainly to small areas of the dorsal prefrontal cortices. Children with ADHD also had reduced brain size in anterior temporal areas, also on both sides of the brain. Substantial increases in grey matter were recorded in large portions of the posterior temporal and inferior parietal cortices in children with ADHD.

Elizabeth R Sowell comments: "Our morphometric procedures allow more precise localisation of group differences than do the methods used in previous studies. Our results therefore suggest that the disturban
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
20-Nov-2003


Page: 1 2

Related medicine news :

1. Brain-imaging cap under study for space and Earth use
2. Brain-imaging study offers clues to inhalant abuse
3. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
4. UMaine study looks at infants and chronic nighttime crying
5. Chronic pain treatments more effective when taken together, new study shows
6. UNC study: Most N.C. family practitioners engage in unrecognized community service
7. New study in Nature demonstrates protection against cell death during heart attack
8. UCSF study offers insight into human circadian rhythms
9. International breast cancer prevention study launches in the United States and Canada
10. UW study shows blacks and Latinos are more satisfied with physicians of the same race
11. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study

Post Your Comments:
(Date:4/25/2015)... 25, 2015 On Friday, April 17, ... Journal’s annual Best Implementation Award. This award is ... best use of RFID technology to improve its manufacturing, ... company that best demonstrates how RFID is delivering real ... RFID Journal Live! 2015 in San Diego, the RFID ...
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The 1975 have had an intense ... globe to theaters, festivals and TV performances. Now that they’ve ... their label, Dirty Hit Records, to provide clean drinking water ... launched Cadence & Cause website, this four-piece has ... and a signed photo card. Entries from this sweepstakes ...
(Date:4/24/2015)... Versailles, KY (PRWEB) April 24, 2015 ... Planning for Medical Field Professionals, today announced their exclusive ... their national Long Term Care Insurance distribution partner. , ... the Long Term Care Insurance benefits for associations, and ... Association for its Long Term Care Insurance member ...
(Date:4/24/2015)... Insuranceautoquote.info has released a new blog post ... , Lowering auto insurance prices is not difficult. ... better offers for their financial budget. Comparing prices by ... require any registration. , Comparing quotes can help ... agencies that sell coverage and this means that clients ...
Breaking Medicine News(10 mins):Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
(Date:4/23/2015)... , Apr. 23, 2015 Surna, Inc. ... and distributes state-of-the art equipment and systems for ... commercial indoor cannabis cultivation, will host a shareholder ... April 27, 2015, at 4:15 PM Eastern Standard ... The conference call will be listen-in only, but ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
Cached News: